Arcellx (ACLX) has drawn attention after fresh performance data on its lead cancer immunotherapies prompted investors to reassess both the company’s clinical pipeline and its recent share price strength over the past 3 months.

Over the past year Arcellx’s share price return of 80.88% year to date and 80.14% over 90 days, compared with a 74.65% one year total shareholder return and 290.09% three year total shareholder return, points to strong momentum around its cancer immunotherapy pipeline, even as the latest close sits at US$114.57.

If Arcellx’s move has you looking at other cancer and AI driven names, this may be a good time to scan the market using our 33 healthcare AI stocks

With Arcellx trading around US$114.57 after a powerful run and sitting slightly above the average analyst price target, the key question now is whether its high intrinsic discount hints at mispricing or whether the market is already baking in future growth.

Preferred Price to Book Multiple of 16.7x: Is it justified?

Arcellx last closed at $114.57 and, on a P/B of 16.7x, screens as good value against its closest peers but expensive against the broader US biotech group.

The price to book ratio compares a company’s market value to its net assets on the balance sheet. It is often used for early stage or loss making businesses where earnings based metrics are less useful. For a biotech focused on cancer immunotherapies, a higher P/B can signal that investors are placing a premium on the clinical pipeline, partnerships and potential future cash flows rather than current profits.

Relative to peer companies with an average P/B of 42.6x, Arcellx’s 16.7x looks restrained, which suggests investors are not paying the highest end multiples seen in its space. However, compared with the wider US Biotechs industry average of 2.2x, the same 16.7x multiple looks rich, indicating the market is assigning Arcellx a much higher valuation than the typical biotech listed in the US.

Result: Price to book ratio of 16.7x (ABOUT RIGHT)

However, the thesis still carries clear risks, including Arcellx’s US$228.934 million net loss and the uncertain outcomes and timelines around its multiple ongoing clinical trials.

Another View: What Does The DCF Say?

While the 16.7x P/B suggests Arcellx sits at a premium to the wider US biotech group, the SWS DCF model paints a very different picture. With an estimated fair value of $491.75 versus the current $114.57, the model points to Arcellx trading at a 76.7% discount. Which signal should matter more to you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arcellx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around valuation and clinical risk can be hard to weigh, so take a moment to review the data yourself and pressure test the thesis using our 2 key rewards and 2 important warning signs

Ready for more investment ideas?

If Arcellx has sharpened your focus, do not stop here. Widen your watchlist with data driven ideas that could suit very different goals and risk levels.

• Target dependable income streams by reviewing companies in the 12 dividend fortresses that may fit a yield focused approach.
• Spot potential mispricing opportunities by scanning the 62 high quality undervalued stocks for companies combining attractive prices with quality fundamentals.
• Prioritize resilience by checking out the 64 resilient stocks with low risk scores to see which businesses currently carry lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.